NCT06675643View on ClinicalTrials.gov

Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity: A Feasibility Study of the Vigilant App (Vigilant-2)

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

March 15, 2026

Study Completion Date

March 15, 2026

Conditions
Malignant Skin NeoplasmMelanoma
Interventions
OTHER

Non-Interventional Study

Non-Interventional study

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06675643 - Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity: A Feasibility Study of the Vigilant App (Vigilant-2) | Biotech Hunter | Biotech Hunter